Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (...

door Hisashi Tanaka, Hiroaki Sakamoto, Takahiro Akita, Fumiyoshi Ohyanagi, Yosuke Kawashima, Yuichi Tambo, Azusa Tanimoto, Atsushi Horiike, Eisaku Miyauchi, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishio
Gepubliceerd in 2022-05-01

Relationship Between Pathologic T1 Categories and Pathologic Factors Affecting Prognosis in Pulmonary Adenocarcinoma

door Hironori Ninomiya, MD, PhD, Kentaro Inamura, MD, PhD, Mingyon Mun, MD, PhD, Makoto Nishio, MD, PhD, Yuichi Ishikawa, MD, PhD
Gepubliceerd in 2022-04-01

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

door Ken Takahashi, Yosuke Seto, Koutaroh Okada, Shinya Uematsu, Ken Uchibori, Mika Tsukahara, Tomoko Oh‐hara, Naoya Fujita, Noriko Yanagitani, Makoto Nishio, Kenichi Okubo, Ryohei Katayama
Gepubliceerd in 2020-03-01

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma

door Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, Kuniko Sunami, Yoshiro Nakahara, Satoru Kitazono, Keita Kudo, Yuichi Tambo, Shintaro Kanda, Noriko Yanagitani, Atsushi Horiike, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Makoto Nishio, Yuichiro Ohe, Yukio Hosomi
Gepubliceerd in 2020-10-01

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

door Makoto Nishio, MD, PhD, Kazuto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Fumio Imamura, MD, PhD, Tomoya Kawaguchi, PhD, Hiroyuki Yamaguchi, MD, PhD, Satoshi Ikeda, MD, PhD, Katsuya Hirano, MD, Carla Visseren-Grul, MD, Matteo Ceccarelli, PharmD, MS, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Tomoko Matsui, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Gepubliceerd in 2022-04-01